Literature DB >> 18799446

Neurologic manifestations of von Hippel-Lindau disease.

John A Butman1, W Marston Linehan, Russell R Lonser.   

Abstract

von Hippel-Lindau disease (VHL) is an autosomal-dominant neoplasia syndrome that is the result of a germline mutation of the VHL tumor suppressor gene on the short arm of chromosome 3. Patients with VHL are predisposed to develop lesions of the central nervous system and viscera. Central nervous system lesions include hemangioblastomas (the most common tumor in VHL) and endolymphatic sac tumors (ELSTs). Visceral manifestations include renal carcinomas and cysts, pancreatic neuroendocrine tumors and cysts, pheochromocytomas, and cystadenomas of the reproductive adnexal organs. Despite their benign pathology, hemangioblastomas and ELSTs are a frequent cause of morbidity and mortality in patients with VHL. Recent molecular biologic investigations into these VHL-associated central nervous system lesions provide new insight into their origin and development. Emerging data from serial imaging and clinical surveillance protocols provide insight into the natural history of these lesions. Because of the dissimilar pathobiology and clinical course between hemangioblastomas and ELSTs, the optimal management strategies for these neurologic manifestations of VHL are very different.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18799446      PMCID: PMC3487164          DOI: 10.1001/jama.300.11.1334

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  55 in total

1.  VHL gene inactivation in an endolymphatic sac tumor associated with von Hippel-Lindau disease.

Authors:  A O Vortmeyer; D Choo; S Pack; E Oldfield; Z Zhuang
Journal:  Neurology       Date:  2000-08-08       Impact factor: 9.910

2.  Mosaicism in von Hippel-Lindau disease: lessons from kindreds with germline mutations identified in offspring with mosaic parents.

Authors:  M T Sgambati; C Stolle; P L Choyke; M M Walther; B Zbar; W M Linehan; G M Glenn
Journal:  Am J Hum Genet       Date:  2000-01       Impact factor: 11.025

Review 3.  Hearing preservation surgery for small endolymphatic sac tumors in patients with von Hippel-Lindau syndrome.

Authors:  Cliff A Megerian; David S Haynes; Dennis S Poe; Daniel I Choo; Thomas J Keriakas; Michael E Glasscock
Journal:  Otol Neurotol       Date:  2002-05       Impact factor: 2.311

4.  Treatment of von Hippel-Lindau retinal hemangioblastoma by the vascular endothelial growth factor receptor inhibitor SU5416 is more effective for associated macular edema than for hemangioblastomas.

Authors:  Jean François Girmens; Ali Erginay; Pascale Massin; Paul Scigalla; Alain Gaudric; Stéphane Richard
Journal:  Am J Ophthalmol       Date:  2003-07       Impact factor: 5.258

Review 5.  Molecular basis of the VHL hereditary cancer syndrome.

Authors:  William G Kaelin
Journal:  Nat Rev Cancer       Date:  2002-09       Impact factor: 60.716

6.  Rapid and durable recovery of visual function in a patient with von hippel-lindau syndrome after systemic therapy with vascular endothelial growth factor receptor inhibitor su5416.

Authors:  Lloyd Paul Aiello; Daniel J George; Mark T Cahill; Jun S Wong; Jerry Cavallerano; Alison L Hannah; William G Kaelin
Journal:  Ophthalmology       Date:  2002-09       Impact factor: 12.079

7.  Surgical management of brainstem hemangioblastomas in patients with von Hippel-Lindau disease.

Authors:  Robert J Weil; Russell R Lonser; Hetty L DeVroom; John E Wanebo; Edward H Oldfield
Journal:  J Neurosurg       Date:  2003-01       Impact factor: 5.115

8.  Surgical management of spinal cord hemangioblastomas in patients with von Hippel-Lindau disease.

Authors:  Russell R Lonser; Robert J Weil; John E Wanebo; Hetty L DeVroom; Edward H Oldfield
Journal:  J Neurosurg       Date:  2003-01       Impact factor: 5.115

9.  The natural history of hemangioblastomas of the central nervous system in patients with von Hippel-Lindau disease.

Authors:  John E Wanebo; Russell R Lonser; Gladys M Glenn; Edward H Oldfield
Journal:  J Neurosurg       Date:  2003-01       Impact factor: 5.115

Review 10.  von Hippel-Lindau disease.

Authors:  Russell R Lonser; Gladys M Glenn; McClellan Walther; Emily Y Chew; Steven K Libutti; W Marston Linehan; Edward H Oldfield
Journal:  Lancet       Date:  2003-06-14       Impact factor: 79.321

View more
  37 in total

1.  Beyond the Knudson's hypothesis in von Hippel-Lindau (VHL) disease-proposing vitronectin as a "gene modifier".

Authors:  Francesco Turturro
Journal:  J Mol Med (Berl)       Date:  2009-06       Impact factor: 4.599

2.  Deletion of the von Hippel-Lindau Gene in Hemangioblasts Causes Hemangioblastoma-like Lesions in Murine Retina.

Authors:  Herui Wang; Matthew J Shepard; Chao Zhang; Lijin Dong; Dyvon Walker; Liliana Guedez; Stanley Park; Yujuan Wang; Shida Chen; Ying Pang; Qi Zhang; Chun Gao; Wai T Wong; Henry Wiley; Karel Pacak; Emily Y Chew; Zhengping Zhuang; Chi-Chao Chan
Journal:  Cancer Res       Date:  2018-01-04       Impact factor: 12.701

Review 3.  T-cell lymphoma with von Hippel-Lindau disease: a rare case report and review of literature.

Authors:  Li-Hong Lou; Hua Shen; Jun Lin; Yi-Wen Yan; Yan Peng; Jian-Hong Lu; Qu Xu; Hai-Qiong Jiang
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

4.  Pazopanib therapy for cerebellar hemangioblastomas in von Hippel-Lindau disease: case report.

Authors:  Betty Y S Kim; Eric Jonasch; Ian E McCutcheon
Journal:  Target Oncol       Date:  2012-02-29       Impact factor: 4.493

5.  Bilateral Optic Nerve Head Angiomas and Retrobulbar Haemangioblastomas in von Hippel-Lindau Disease.

Authors:  Masoud Aghsaei Fard; Narges Hassanpoor; Razieh Parsa
Journal:  Neuroophthalmology       Date:  2014-09-19

6.  Biological and clinical impact of hemangioblastoma-associated peritumoral cysts in von Hippel-Lindau disease.

Authors:  Kristin Huntoon; Tianxia Wu; J Bradley Elder; John A Butman; Emily Y Chew; W Marston Linehan; Edward H Oldfield; Russell R Lonser
Journal:  J Neurosurg       Date:  2015-10-30       Impact factor: 5.115

7.  Multiple endocrine neoplasms and serous cysts of the pancreas in a patient with von Hippel-Lindau disease.

Authors:  Hiroyuki Matsubayashi; Katsuhiko Uesaka; Hideyuki Kanemoto; Teiichi Sugiura; Takashi Mizuno; Keiko Sasaki; Hiroyuki Ono; Ralph Hruban
Journal:  J Gastrointest Cancer       Date:  2010-09

8.  Repurposing propranolol as an antitumor agent in von Hippel-Lindau disease.

Authors:  Matthew J Shepard; Alejandro Bugarini; Nancy A Edwards; Jie Lu; Qi Zhang; Tianxia Wu; Zhengping Zhuang; Prashant Chittiboina
Journal:  J Neurosurg       Date:  2018-10-01       Impact factor: 5.115

9.  Prospective natural history study of central nervous system hemangioblastomas in von Hippel-Lindau disease.

Authors:  Russell R Lonser; John A Butman; Kristin Huntoon; Ashok R Asthagiri; Tianxia Wu; Kamran D Bakhtian; Emily Y Chew; Zhengping Zhuang; W Marston Linehan; Edward H Oldfield
Journal:  J Neurosurg       Date:  2014-02-28       Impact factor: 5.115

Review 10.  Familial syndromes associated with intracranial tumours: a review.

Authors:  Adrianna M Ranger; Yatri K Patel; Navjot Chaudhary; Ram V Anantha
Journal:  Childs Nerv Syst       Date:  2013-11-06       Impact factor: 1.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.